Glenmark Pharmaceuticals Limited

₹2,595As of Sun 8 Nov 2026, 12:00 UTC
NSE:GLENMARKHealthcare
Country India
PE (Fwd) •••
TSR 10Y CAGR 11.12%
Div yield 0.19%
ROE 13.96%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.27
PE TTM 50.47
TSR TTM 37.35%
Mkt cap ₹732.3B
ROIC 18.27%
SE Grade™
Value
Quality
Moat
Consensus
Reference
₹3,322
28.00%
(90.75%)
Hold 3|1|3|5|1
3Q26
4Q26
1Q27
2Q27
Earnings per share₹
27.46
30.58
33.83
32.20
14.27%
28.56%
30.99%
25.26%
Revenue₹B
58.86
59.66
62.43
62.96
(1.49%)
(1.56%)
2.26%
4.70%
Peers (US$7.783B)
Cap (US$)
PE
9.689B
17.52x
6.744B
29.36x
5.968B
33.91x
7.713B
—
Capital
TTM
5Y
10Y
Leveragex
4.879
6.238
4.757
EBIT/Intx
8.905
0.606
0.670
Own earn%
16.55
(11.78)
(7.82)
Sh yield%
34.50
31.24
29.21
Owners
Insiders/Inst%
5.84
39.70
Short interest%
1.52
SBC / revenue%
0.80
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
12
Op margin range%
3–9
$1 testx
—
Incr. ROIC%
1